(Q28066316)

protein kinase inhibitors

main subject

1 reference

28 September 2019

1 reference

7 November 2019

1 reference

7 November 2019

tumor of hematopoietic and lymphoid tissues

1 reference

22 July 2020

Jingjing Wu

1

1 reference

Mingzhi Zhang

series ordinal

2

1 reference

Delong Liu

series ordinal

3

1 reference

Journal of Hematology & Oncology

language of work or name

1 reference

9 March 2016

7 references

3 April 2019

17 September 2019

28 September 2019

2 October 2019

7 November 2019

22 July 2020

6 references

3 April 2019

17 September 2019

28 September 2019

2 October 2019

7 November 2019

22 July 2020

9

1 reference

issue

1

0 references

page(s)

21

1 reference

Creative Commons Attribution 4.0 International

copyright license

6 references

3 April 2019

17 September 2019

28 September 2019

2 October 2019

7 November 2019

on focus list of Wikimedia project

22 July 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Ibrutinib in previously treated Waldenström's macroglobulinemia.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

New antibody approaches to lymphoma therapy

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Novel ALK inhibitors in clinical use and development.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Selective inhibitors of nuclear export (SINE) in hematological malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Ibrutinib for B cell malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4784459

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

2 June 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13045-016-0250-9

Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13045-016-0250-9

Movement toward Optimization of CLL Therapy

21 January 2018

1 reference

12 December 2020

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

1 reference

12 December 2020

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

1 reference

12 December 2020

Blinatumomab: a new era of treatment for adult ALL?

1 reference

12 December 2020

10.1186/S13045-016-0250-9

Identifiers

DOI

1 reference

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s13045-016-0250-9

1 reference

1 reference

PubMed publication ID

26957112

1 reference